Literature DB >> 24670318

Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.

George K Lewis1, Yongjun Guan, Roberta Kamin-Lewis, Mohammad Sajadi, Marzena Pazgier, Anthony L Devico.   

Abstract

PURPOSE OF REVIEW: This review analyzes recent studies suggesting that highly conserved epitopes in the HIV-1 Env trimer are targets of potentially protective nonneutralizing antibodies that mediate antibody-dependent cellular cytotoxicity. RECENT
FINDINGS: Recent studies in both non-human primates and humans suggest that nonneutralizing antibodies play a role in blocking infection with hybrid simian HIV (SHIV)/simian immunodeficiency virus (SIV) or HIV-1 by Fc-mediated effector function, in particular antibody-dependent cellular cytotoxicity. Further, several studies implicate highly conserved epitopes in the C1 region of gp120 as targets of these antibodies. However, these suggestions are controversial, as passive immunization studies do not indicate that such antibodies can block acquisition in non-human primates. Potential reasons for this discrepancy are discussed in the structural context of potent antibody-dependent cellular cytotoxicity epitopes on target cells during the narrow window of opportunity when antibodies can block HIV-1 acquisition.
SUMMARY: Cumulative evidence suggests that, in addition to virus neutralization, Fc-mediated effector responses to highly conserved epitopes in the HIV-1 trimer play distinct as well as overlapping roles in blocking HIV-1 acquisition. Evidence will be discussed as to whether nonneutralizing antibodies specific for epitopes on the HIV-1 Env trimer that become exposed during viral entry contribute significantly to blocking HIV-1 acquisition.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24670318      PMCID: PMC4104495          DOI: 10.1097/COH.0000000000000055

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  70 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

3.  Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.

Authors:  Peng Xiao; L Jean Patterson; Seraphin Kuate; Egidio Brocca-Cofano; Michael A Thomas; David Venzon; Jun Zhao; Janet DiPasquale; Claudio Fenizia; Eun Mi Lee; Irene Kalisz; Vaniambadi S Kalyanaraman; Ranajit Pal; David Montefiori; Brandon F Keele; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Authors:  Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-13       Impact factor: 11.205

5.  A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Authors:  Brian Moldt; Niccole Schultz; D Cameron Dunlop; Michael D Alpert; Jackson D Harvey; David T Evans; Pascal Poignard; Ann J Hessell; Dennis R Burton
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Authors:  Robert Pejchal; Katie J Doores; Laura M Walker; Reza Khayat; Po-Ssu Huang; Sheng-Kai Wang; Robyn L Stanfield; Jean-Philippe Julien; Alejandra Ramos; Max Crispin; Rafael Depetris; Umesh Katpally; Andre Marozsan; Albert Cupo; Sebastien Maloveste; Yan Liu; Ryan McBride; Yukishige Ito; Rogier W Sanders; Cassandra Ogohara; James C Paulson; Ten Feizi; Christopher N Scanlan; Chi-Huey Wong; John P Moore; William C Olson; Andrew B Ward; Pascal Poignard; William R Schief; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2011-10-13       Impact factor: 47.728

7.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors:  Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

8.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Authors:  Ann J Hessell; Pascal Poignard; Meredith Hunter; Lars Hangartner; David M Tehrani; Wim K Bleeker; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440

9.  ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Authors:  Michael D Alpert; Jackson D Harvey; W Anderson Lauer; R Keith Reeves; Michael Piatak; Angela Carville; Keith G Mansfield; Jeffrey D Lifson; Wenjun Li; Ronald C Desrosiers; R Paul Johnson; David T Evans
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

10.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962

View more
  25 in total

1.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

2.  Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission.

Authors:  Mileidy W Gonzalez; Anthony L DeVico; George K Lewis; John L Spouge
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

3.  CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Wen Shi Lee; Jérémie Prévost; Jonathan Richard; Reneé M van der Sluis; Sharon R Lewin; Marzena Pazgier; Andrés Finzi; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

Review 4.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 5.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

Review 6.  Animal models in HIV-1 protection and therapy.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

7.  Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.

Authors:  Neelakshi Gohain; William D Tolbert; Priyamvada Acharya; Lei Yu; Tongyun Liu; Pingsen Zhao; Chiara Orlandi; Maria L Visciano; Roberta Kamin-Lewis; Mohammad M Sajadi; Loïc Martin; James E Robinson; Peter D Kwong; Anthony L DeVico; Krishanu Ray; George K Lewis; Marzena Pazgier
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

8.  Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Authors:  Yunda Huang; Guido Ferrari; Galit Alter; Donald N Forthal; John C Kappes; George K Lewis; J Christopher Love; Bhavesh Borate; Linda Harris; Kelli Greene; Hongmei Gao; Tran B Phan; Gary Landucci; Brittany A Goods; Karen G Dowell; Hao D Cheng; Chris Bailey-Kellogg; David C Montefiori; Margaret E Ackerman
Journal:  J Immunol       Date:  2016-11-09       Impact factor: 5.422

9.  Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Authors:  Priyamvada Acharya; William D Tolbert; Neelakshi Gohain; Xueji Wu; Lei Yu; Tongyun Liu; Wensheng Huang; Chih-Chin Huang; Young Do Kwon; Robert K Louder; Timothy S Luongo; Jason S McLellan; Marie Pancera; Yongping Yang; Baoshan Zhang; Robin Flinko; James S Foulke; Mohammad M Sajadi; Roberta Kamin-Lewis; James E Robinson; Loïc Martin; Peter D Kwong; Yongjun Guan; Anthony L DeVico; George K Lewis; Marzena Pazgier
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

10.  Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.

Authors:  William D Tolbert; Neelakshi Gohain; Nirmin Alsahafi; Verna Van; Chiara Orlandi; Shilei Ding; Loïc Martin; Andrés Finzi; George K Lewis; Krishanu Ray; Marzena Pazgier
Journal:  Structure       Date:  2017-10-19       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.